ArticleJournal of virology2007
Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression.
Article in Journal of virology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Characterisation of HIV-1 Gag Cytotoxic T-Lymphocyte Epitopes in the Southern African Region-A Systematic Review.Immunology · 2026Pooled it
- Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection.PLoS pathogens · 2016Trial
- Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial.The Journal of infectious diseases · 2011Trial
- HLA Class I (A and B) Allele Polymorphism in a Moroccan Population Infected with Hepatitis C Virus.Current issues in molecular biology · 2024Article
- No Difference in the Prevalence of HIV-1Vaccines · 2023Article
- Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8Nature communications · 2022Article
- Immunoescape of HIV-1 in Env-EL9 CD8 + T cell response restricted by HLA-B*14:02 in a Non progressor who lost twenty-seven years of HIV-1 control.Retrovirology · 2022Article
- Structural Basis for Unusual TCR CDR3β Usage Against an Immunodominant HIV-1 Gag Protein Peptide Restricted to an HLA-B*81:01 Molecule.Frontiers in immunology · 2022Article
- Article
- Exome Sequencing Reveals a Putative Role for HLA-C*03:02 in Control of HIV-1 in African Pediatric Populations.Frontiers in genetics · 2021Article
- TLR agonists enhance responsiveness of inflammatory innate immune cells in HLA-B*57-positive HIV patients.Journal of molecular medicine (Berlin, Germany) · 2021Article
- Primary HIV-1 Strains Use Nef To Downmodulate HLA-E Surface Expression.Journal of virology · 2019Article
- Mapping the drivers of within-host pathogen evolution using massive data sets.Nature communications · 2019Article
- Dual HLA B*42 and B*81-reactive T cell receptors recognize more diverse HIV-1 Gag escape variants.Nature communications · 2018Article
- Pol-Driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection.Journal of virology · 2018Article
- Resistance of Major Histocompatibility Complex Class B (MHC-B) to Nef-Mediated Downregulation Relative to that of MHC-A Is Conserved among Primate Lentiviruses and Influences Antiviral T Cell Responses in HIV-1-Infected Individuals.Journal of virology · 2018Article
- Hepatitis B Virus Adaptation to the CD8+ T Cell Response: Consequences for Host and Pathogen.Frontiers in immunology · 2018Review
- HIV-1 adaptation to NK cell-mediated immune pressure.PLoS pathogens · 2017Article
- Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Natural Killer Cell Interactions with Classical and Non-Classical Human Leukocyte Antigen Class I in HIV-1 Infection.Frontiers in immunology · 2017Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
The possession of some HLA class I molecules is associated with delayed progression to AIDS. The mechanism behind this beneficial effect is unclear. We tested the idea that cytotoxic T-cell responses restricted by advantageous HLA class I molecules impose stronger selection pressures than those restricted by other HLA class I alleles. As a measure of the selection pressure imposed by HLA class I alleles, we determined the extent of HLA class I-associated epitope variation in a cohort of European human immunodeficiency virus (HIV)-positive individuals (n=84). We validated our findings in a second, distinct cohort of African patients (n=516). We found that key HIV epitopes restricted by advantageous HLA molecules (B27, B57, and B51 in European patients and B5703, B5801, and B8101 in African patients) were more frequently mutated in individuals bearing the restricting HLA than in those who lacked the restricting HLA class I molecule. HLA alleles associated with clinical benefit restricted certain epitopes for which the consensus peptides were frequently recognized by the immune response despite the circulating virus's being highly polymorphic. We found a significant inverse correlation between the HLA-associated hazard of disease progression and the mean HLA-associated prevalence of mutations within epitopes (P=0.028; R2=0.34). We conclude that beneficial HLA class I alleles impose strong selection at key epitopes. This is revealed by the frequent association between effective T-cell responses and circulating viral escape mutants and the rarity of these variants in patients who lack these favorable HLA class I molecules, suggesting a significant pressure to revert.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.